ESR1 and inflammatory breast carcinoma: This is the first report to examine mutations specifically in HR + IBC patients exposed to CDKI and demonstrates rates of acquired ESR1 mutations comparble to those reported in non-IBC [27, 28] and multiple actionable mutations, including BRCA.